Breaking News, Collaborations & Alliances

I-Mab Biopharma and Bio-Cancer Treatment Int’l Team Up

Will explore biotherapeutics and biomarkers based on arginine metabolism in human malignancies and autoimmune disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

I-Mab Biopharma, a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, has entered into a memorandum of understanding (MOU) with Hong Kong-based Bio-Cancer Treatment International Limited (BCT) to jointly explore and investigate new therapeutic potentials for BCT’s arginine depletion therapy in autoimmune diseases and cancers.   Under the terms of the MOU, I-Mab and BCT will work tog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters